The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.95
Bid: 34.85
Ask: 35.00
Change: 0.05 (0.14%)
Spread: 0.15 (0.43%)
Open: 35.75
High: 35.75
Low: 34.45
Prev. Close: 34.90
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Holdings

24 May 2018 16:05

RNS Number : 2438P
Alliance Pharma PLC
24 May 2018
 

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Alliance Pharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Details of person subject to the notification obligation

Name

GVQ Investment Management Limited

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)

Name

Chase Nominees Ltd & Nortrust Nominees Ltd

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached:

23/05/18

6. Date on which issuer notified (DD/MM/YYYY):

24/05/18

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.98%

4.98%

475,410,395

Position of previous notification (if

applicable)

5.05%

5.05%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0031030819

23,691,460

4.98%

SUBTOTAL 8. A

23,691,460

4.98%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Physical or cash

settlement

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information

 

Place of completion

London, SW1A 1NX

Date of completion

24/05/18

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEASSLAEAPEFF
Date   Source Headline
6th Dec 20187:00 amRNSTotal Voting Rights
12th Nov 20183:51 pmRNSDirector Share Dealing
7th Nov 20181:35 pmEQSHardman & Co Research: Alliance Pharma (APH): International brands driving performance
5th Oct 201810:25 amRNSGrant of Options to Directors
2nd Oct 20187:00 amRNSXonvea launch in the UK
19th Sep 20187:00 amRNSInterim results
16th Aug 20187:00 amRNSNotice of Results
10th Aug 201810:00 amRNSTotal Voting Rights
1st Aug 20189:56 amEQSHardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress
25th Jul 20187:00 amRNSHalf Year Trading Update
6th Jul 20187:00 amRNSMarketing Authorisation for Diclectin
29th Jun 20187:00 amRNSBlock Listing Six Monthly Return
25th Jun 20189:39 amRNSNotification of Major Holdings
22nd Jun 201811:58 amRNSNotification of Major Holdings
21st Jun 20184:13 pmRNSCompletion of Acquisition and TVR
19th Jun 20182:24 pmRNSResult of Placing
19th Jun 20187:00 amRNSNizoral Acquisition in APAC and Proposed Placing
18th Jun 20185:19 pmRNSNotification of Major Holdings
18th Jun 20185:17 pmRNSNotification of Major Holdings
7th Jun 20187:00 amRNSPositive Opinion on Diclectin
5th Jun 20181:03 pmRNSTotal Voting Rights
30th May 20187:00 amRNSDirectorate Change
24th May 20184:05 pmRNSNotification of Major Holdings
24th May 201811:00 amRNSResult of AGM
24th May 20187:00 amRNSAGM Statement
16th May 20183:05 pmRNSNotification of Major Holdings
2nd May 201812:32 pmRNSTotal Voting Rights
19th Apr 20185:25 pmRNSAnnual Report and AGM Notice
19th Apr 20184:59 pmRNSNotification of Major Holdings
19th Apr 20187:17 amEQSHardman & Co Research: Alliance Pharma (APH): Entering the US market
17th Apr 20187:00 amRNSDisposal of Chinese rights to Forceval
13th Apr 20187:00 amRNSAlliance to present at the UK Investor Show
3rd Apr 20184:09 pmRNSTotal Voting Rights
27th Mar 20187:00 amRNSFull Year Results
6th Mar 20181:48 pmRNSTotal Voting Rights
1st Mar 20187:00 amRNSDirectorate Changes
8th Feb 20185:49 pmRNSTotal Voting Rights
8th Feb 20185:47 pmRNSNotification of Major Holdings
8th Feb 20187:00 amRNSNotification of Preliminary Results
29th Jan 201811:20 amRNSHardman Research: Strong Operational Cashflow
22nd Jan 20187:00 amRNSPre-Close Trading Update
11th Jan 20187:15 amRNSHardman Research: Acquisitions to boost growth
2nd Jan 20182:00 pmRNSTotal Voting Rights
2nd Jan 20187:00 amRNSBlock Listing Six Monthly Return
28th Dec 20177:00 amRNSCompletion of acquisition of Vamousse
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
1st Dec 20177:00 amRNSAcquisition of AmetopT
17th Oct 20179:14 amRNSHardman Research: Kelo-cote international sales

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.